{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Recurrent+Central+Nervous+System+Tumors",
    "query": {
      "condition": "Pediatric Recurrent Central Nervous System Tumors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 116,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Recurrent+Central+Nervous+System+Tumors&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:40:35.013Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07087002",
      "title": "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Medulloblastoma",
        "Central Nervous System Embryonal Tumor",
        "Refractory Medulloblastoma",
        "Recurrent Medulloblastoma",
        "Pediatric Brain Tumor",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Pineoblastoma",
        "Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS",
        "CNS Neuroblastoma",
        "FOXR2-activated"
      ],
      "interventions": [
        {
          "name": "GPC2-CAR T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-08-28",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07087002"
    },
    {
      "nct_id": "NCT04525014",
      "title": "RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor, Recurrent",
        "Brain Tumor, Pediatric",
        "Central Nervous System Neoplasms",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "RRx-001",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpicentRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 2,
      "start_date": "2023-01-26",
      "completion_date": "2024-07-29",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04525014"
    },
    {
      "nct_id": "NCT01737671",
      "title": "Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Brain Tumor",
        "Malignant Neoplasm of Fourth Ventricle of Brain"
      ],
      "interventions": [
        {
          "name": "Ommaya Reservoir",
          "type": "PROCEDURE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "Up to 22 Years"
      },
      "enrollment_count": 7,
      "start_date": "2012-12-27",
      "completion_date": "2018-01-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-19",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01737671"
    },
    {
      "nct_id": "NCT00024258",
      "title": "Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Liver Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "arsenic trioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 22,
      "start_date": "2001-03",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2015-11-25",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024258"
    },
    {
      "nct_id": "NCT00883688",
      "title": "Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Pediatric Cancers"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2020-08-26",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00883688"
    },
    {
      "nct_id": "NCT05096481",
      "title": "PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Diffuse Intrinsic Pontine Glioma",
        "Recurrent Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "PEP-CMV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tetanus Diphtheria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-07-18",
      "completion_date": "2030-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 13,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096481"
    },
    {
      "nct_id": "NCT01188096",
      "title": "A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumors"
      ],
      "interventions": [
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-08",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188096"
    },
    {
      "nct_id": "NCT02444546",
      "title": "Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Astrocytoma",
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Diffuse Intrinsic Pontine Glioma",
        "Glioma",
        "Recurrent Childhood Anaplastic Oligodendroglioma",
        "Recurrent Childhood Brain Neoplasm",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Primitive Neuroectodermal Tumor",
        "Refractory Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wild-type Reovirus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-06-21",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02444546"
    },
    {
      "nct_id": "NCT00600054",
      "title": "Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Pontine Gliomas"
      ],
      "interventions": [
        {
          "name": "nimotuzumab (anti EGFR humanized monoclonal antibody)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "YM BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 44,
      "start_date": "2007-10",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-07-06",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600054"
    },
    {
      "nct_id": "NCT01132911",
      "title": "A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Sarcoma",
        "WilmsTumor",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Vorinostat (SAHA)",
          "type": "DRUG"
        },
        {
          "name": "Velcade (PS-341, Bortezomib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 5,
      "start_date": "2010-05-10",
      "completion_date": "2011-04-13",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-23T22:40:35.013Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132911"
    }
  ]
}